Analysen von Chris Shibutani
| 06.08.24 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 07.05.24 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 21.03.24 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 08.11.23 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 07.11.23 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 05.06.23 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 09.05.23 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 26.04.23 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
|
Werbung
|
|||
| 28.03.23 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 16.01.23 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 08.11.22 | Pfizer Neutral | Goldman Sachs Group Inc. | |
| 08.11.22 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 14.10.22 | Pfizer Neutral | Goldman Sachs Group Inc. | |
| 26.08.22 | Pfizer Neutral | Goldman Sachs Group Inc. | |
| 09.08.22 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 29.07.22 | Pfizer Neutral | Goldman Sachs Group Inc. | |
| 13.07.22 | Pfizer Neutral | Goldman Sachs Group Inc. | |
| 30.06.22 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 15.06.22 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 25.05.22 | Pfizer Neutral | Goldman Sachs Group Inc. | |
| 11.05.22 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 04.05.22 | Pfizer Neutral | Goldman Sachs Group Inc. | |
| 01.04.22 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 09.02.22 | Pfizer Neutral | Goldman Sachs Group Inc. | |
| 08.02.22 | Pfizer Neutral | Goldman Sachs Group Inc. | |
| 19.01.22 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 12.01.22 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 07.01.22 | Pfizer Neutral | Goldman Sachs Group Inc. | |
| 17.12.21 | Pfizer Neutral | Goldman Sachs Group Inc. | |
| 24.09.21 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |
| 23.09.21 | BioNTech (ADRs) Neutral | Goldman Sachs Group Inc. | |